A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae

Accurate marrow dosimetry for radionuclide therapy based on imaging methods has been challenging because of a variety of factors. One of the uncertainties in image quantification of lumbar vertebrae is correction for radioactivity in large blood vessels anterior to the vertebrae. We developed a method to correct for background radioactivity contributed from blood in large vessels and tested it in a pilot study. Methods: CT images of 26 patients receiving 111In- or 131I-labeled conjugates were used to measure the inside diameters of the aorta and inferior vena cava (IVC) at the top of L2 and the bottom of L4 and to measure the length of this vessel segment. The volume was calculated for this vessel segment, and then the radioactivity in that volume at each imaging time was determined using a time-variant blood radioactivity concentration as established by serial blood samples. This vessel segment typically overlapped with lumbar vertebrae in anterior and posterior whole-body images. The contribution of this background radioactivity to the cumulated activity of the lumbar spine region of interest (ROI) from serial γ-camera images was determined, taking into account differences in attenuation between vessel segments and lumbar vertebrae. Results: The total blood volumes varied from 25 to 94 mL, with a mean of 51 mL. This mean is 76% of the mean marrow volume of 3 lumbar vertebrae measured in some of these patients. Thirteen of the 14 patients evaluated for aortic position had the aortic segment completely within the L2–L4 ROI. For the IVC, a mean of 72% was in the L2–L4 ROI. Adjusting for radioactivity in major blood vessels that were in the ROI led to lower marrow dose estimates. Conclusion: To improve the accuracy of lumbar spine imaging-based marrow dosimetry, one can adjust radioactivity in the large vessels by methods that measure the volume, position, and depth of vessels in the ROI.

[1]  W. Bolch,et al.  Correlations of total pelvic spongiosa volume with both anthropometric parameters and computed tomography-based skeletal size measurements. , 2006, Cancer biotherapy & radiopharmaceuticals.

[2]  S. Shen,et al.  Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  S. Strand,et al.  Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy , 2005, Acta oncologica.

[4]  J. Bouček,et al.  Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  J. Schlom,et al.  Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer , 2004 .

[6]  J. Vose,et al.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.

[7]  J. Schlom,et al.  A novel monoclonal antibody design for radioimmunotherapy. , 2003, Cancer biotherapy & radiopharmaceuticals.

[8]  S. Shen,et al.  Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  W. Bolch,et al.  Considerations of anthropometric, tissue volume, and tissue mass scaling for improved patient specificity of skeletal S values. , 2002, Medical physics.

[10]  Wesley E Bolch,et al.  Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Y. Erdi,et al.  Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.

[12]  Daniel H. S. Silverman,et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.

[13]  G. Denardo,et al.  Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  S. Larson,et al.  Bone marrow dosimetry: regional variability of marrow-localizing antibody. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Shen,et al.  Estimation of Radiation Absorbed Doses to the Red Marrow in Radioimmunotherapy , 1995, Clinical Nuclear Medicine.

[16]  G Sgouros,et al.  Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Schlom,et al.  Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  G. Denardo,et al.  Biology of radionuclide therapy , 1989 .

[19]  R. E. Lee,et al.  Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. , 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.